SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F
Retrieved on:
月曜日, 4月 29, 2024
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, Heng, NMPA, The Twelve Months, Vaccine, Enterovirus, District court, Court, GAAP, Person, EV71, WHO, Hearing, National Medical Products Administration, Hand, Exchange, Complaint, Sinovac Biotech, Privy council, Good, Annual report, Influenza, Infection, OrbiMed, Motion, Foot, Judgement, Rights, GMP, Clinical trial, Government, Appellate court, Medication, Capital, Ageing, Influenza vaccine, Cancer, Trust, Bank statement, HFMD, COVID-19, Growth, Hepatitis
The Company also reported its unaudited financial results for the second half and audited financial for the full year ended December 31, 2023.
Key Points:
- The Company also reported its unaudited financial results for the second half and audited financial for the full year ended December 31, 2023.
- Sales for the second half of 2023 were $307.9 million, compared to $280.5 million in the prior year period.
- R&D expenses in the second half of 2023 were $193.4 million, compared to $257.7 million in the prior year period.
- The Company’s financial statements for the second half of 2023 are prepared and presented in accordance with U.S. GAAP.